“Stroke caused by AF tends to be severe and is associated with significant mortality and morbidity. The average costs of both health and social care for stroke have recently been calculated to be an average of £44,434 over the first 5 years…. Detecting AF through opportunistic pulse checks would cost virtually nothing. Anticoagulating these patients requires effective delivery systems and enhanced communication between all those responsible for patient care. Many patients can be managed perfectly well with warfarin, which is a cheap and effective anticoagulant when managed correctly. Increasingly, the advantages of the newer oral anticoagulants are being recognised by both clinicians and patients. Although these drugs are relatively expensive, the cost is considerably less than the costs for one person who experiences a stroke” Tony Rudd CBE National Clinical Director for Stroke, NHS England Matt Kearney National Clinical Director for cardiovascular prevention, NHS England“NHS England and Public Health England have identified the scale of the benefits that can be realised through coordinated and focused quality improvement programmes. They estimate that over 14,000 strokes in England could be avoided over three years, if everyone with AF was diagnosed and received appropriate anticoagulation therapy, and over £240m in financial savings could be delivered by optimising AF treatment” Out of Range, Audit of Anticoagulation Management in Secondary Care in England, Anticoagulation UK May 2018“Illnesses relating to atrial fibrillation (AF), including stroke, cost the NHS over £2.2 billion each year and there are growing concerns about variations in the quality of AF care across England.” Anticoagulation UK 2018“Even when people with AF are correctly diagnosed and treatment is started, strokes still can and do occur, often due to poor quality of anticoagulation control and poor adherence to treatment. Sub-analysis of national audit data shows that 83 per cent of stroke patients with known AF, who were prescribed an anticoagulant, were found to have inadequate control and, therefore, at increased risk of stroke or bleeding” Out of Range, Audit of Anticoagulation Management in Secondary Care in England, Anticoagulation UK May 2018This conference focuses on optimising anticoagulation therapy for all patients: improving outcomes and patient safety and will enable you to:Network with colleagues who are working to optimise Anticoagulation TherapyLearn from outstanding practice in Atrial Fibrillation: Detect, Protect and PerfectReflect on national developments and learning including adherence to the National Quality Standard for Atrial Fibrillation, and the recent Audit of Anticoagulation Management in Secondary Care in EnglandImprove the way patients are supported to self-manage and self-monitorUnderstand Complex anticoagulation issues including anticoagulation in the frail, restarting anticoagulation after a bleed, oral anticoagulants combined with anti-platelet drugsDevelop your skills in optimizing patients on anticoagulation therapySelf-assess your service against components of an excellent anticoagulation serviceUnderstand how you can improve initiation of anticoagulation therapyIdentify key strategies for warfarin and NOAC monitoringSelf-assess and reflect on your own practiceGain CPD accreditation points contributing to professional development and revalidation evidence